Articles from Talus Bioscience

Talus Bioscience, a technology-enabled therapeutics company, today announced new preclinical data from programs targeting transcription factors in chordoma, non-small cell lung cancer, and advanced prostate cancer. The data, presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting, held April 25-30, support Talus Bio’s first-in-class approach to target previously undruggable transcription factors using regulome-scale discovery in live human cells.

Talus Bioscience, a drug discovery company founded by a world-class team of scientific leaders in proteomics, biochemistry, and machine learning, today announced $11.2M in new venture funding. The Seed+ round was led by Two Bear Capital, with participation from WRF Capital, NFX, YC Continuity Fund, Funders Club VC, and BoxOne Ventures.